Info Request

Patient recruitment for our first RepliCel™ clinical trial is now complete.

Our clinical team has initiated discussions with regulators in Europe and Canada in anticipation of positive data from our ongoing phase I/IIa clinical trial. Once approval to conduct those trials has been obtained and clinical sites have been selected, there will be an opportunity for patients to qualify to be study participants. Note that patients that do qualify for study participation will be required to make frequent clinical site visits to ensure their safety and to monitor the effects of the RepliCel™ procedure, as such, patient proximity to a patient trial site is an important consideration.

Information on upcoming clinical trials will be sent to you, as will information on how potential study participants can qualify for study participation.

To unsubscribe from receiving requested info, please click here and type "unsubscribe" in the email subject line.

Please be advised that the company cannot provide medical advice.